Slight change of pace, for something different going back to...

Slight change of pace, for something different going back to this years great financials for Clinuvel and a comparison to Pro Medicus - PME another rare Biotech like CUV who have been growing revenue and profits for quite a few years now.

Pro Medicus FY2024 Revenue $161 Million, Profit after tax $82.8Million. Market cap $18 Billion. P/E 217
Clinuvel, FY2024 Revenue $95 Million, Profit after tax $35.6Million. Market cap $0.7 Billion. P/E 20

With Clinuvel forecasts for Vitiligo which is in Phase 3 the CUV Revenues and Profits should go past PME IMO in just a few years if approved. Shorters painting a picture that everything will not work for Clinuvel but financials show this is not right as they keep on growing and slowly progressing their pipeline which is based around a drug that ALREADY has the all important FDA approval. Whenever I look at this comparison it always gives me a laugh to think Pro Medicus could just dilute their shares 10%, raise $2 Billion cash and immediately take over Clinuvel for that money. It would give them an instant 50% boost to Revenues/Profits and dramatically decrease their P/E and at the same time making their risk/reward profile much better. Stranger things have happened, the cash printing machine at CUV must be attracting some investigations at these manipulated levels IMO from somewhere, nearly $18 Billion higher valuation for $46 Million more profit is interesting when both companies are growing nicely albeit PME at a quicker rate.

All IMO DYOR